Drug Recall: Glimepiride 4 mg for Manufacturing Practice Deviations
PD-Rx Pharmaceuticals is recalling 186 bottles of Glimepiride USP 4 mg due to manufacturing deviations. Patients using this medication should contact their healthcare provider to verify if their supply is affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall without reported illnesses or injuries. Voluntary precautionary recall initiated by the manufacturer due to manufacturing process deviations. Meets the rubric criteria for moderate-severity quality control issues without reported harm.
Plain-English summary
PD-Rx Pharmaceuticals, Inc. is recalling 186 bottles of Glimepiride USP 4 mg tablets that were distributed nationwide in the United States. The affected product is packaged at the company's Oklahoma City, Oklahoma facility and carries NDC number 43063-0587-90.
The FDA determined that the manufacturer had deviations from Current Good Manufacturing Practices (CGMP) standards during production. The company voluntarily initiated the recall on April 6, 2023. The recall was terminated on April 30, 2024.
Patients taking Glimepiride should consult their healthcare provider to determine whether their medication is from one of the affected lots and to discuss any needed alternatives. Specific lot numbers and expiration dates are available through the FDA recall notice. The affected lots have expiration dates ranging from January 2024 to June 2025.
The recalled product
- Product
- Glimepiride USP, 4 mg, 90 count-bottles, Rx only, Intas Pharm. Limited Pkg By: PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127, NDC 43063-0587-90
- Manufacturer
- PD-Rx Pharmaceuticals, Inc.
- Category
- Drug
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- Lots: A22B45 Exp. 01/31/24
- C22A73
- E22E41
- C22D28
- F22B68
- G22A29
- H22B97
- K22A36 Exp. 03/31/24
- K22B99
- A23D07
- B23B25 Exp. 10/31/24
- B23B55 Exp. 06/30/25
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27